The Drug Enforcement Administration (DEA) is telling lawmakers that it reserves "the final authority" to make any scheduling decision on marijuana, despite growing pressure for rescheduling from various states and advocacy groups.
With the cannabis industry eagerly awaiting the U.S. Drug Enforcement Administration's latest move in the rescheduling process, the new year brings renewed hope for potential changes in federal marijuana policies.
The Drug Enforcement Administration (DEA) is now calling for the production of even more THC, psilocybin, and DMT for research purposes than ever before, signaling a potential shift in the agency's approach to studying these substances.
Legalization advocates argue that reclassifying marijuana from Schedule I to Schedule III doesn't fully resolve the conflicts between state and federal laws, leaving room for continued legal ambiguity.
The state of Georgia's medical marijuana program finds itself in the crosshairs of the federal government, as the Drug Enforcement Administration (DEA) raises concerns about the state's approach to medical cannabis.
The U.S. Drug Enforcement Administration is warning Georgia against moving forward with its plan to become the first state to allow pharmacies to dispense medical marijuana. The federal agency asserts that such actions would be in violation of federal law.
DEA Threatens Georgia Pharmacies Over Dispensing medical marijuana Under State Law ... Georgia recently became the first U.S. state to allow the dispensing of medical marijuana through pharmacies, but now faces pushback from the federal government.
A Republican congressman, while personally opposed to marijuana Legalization, acknowledges the need to reconsider its federal scheduling to address the growing demand and conflicts between state and federal laws.
The governors of six U.S. states—Colorado, Illinois, New York, New Jersey, Maryland, and Louisiana—have sent a letter to President Joe Biden, urging him to consider the rescheduling of marijuana and aligning federal policies with state laws.
The ongoing debate surrounding marijuana rescheduling highlights the complex dynamics between federal and state jurisdictions, as well as the increasing pressure on the DEA to address the shifting attitudes towards cannabis.
Advocates argue that rescheduling marijuana to a lower schedule would provide greater access to medical patients, promote research, and reduce the potential for federal intervention in states with legal cannabis.
Opponents of marijuana rescheduling express concerns about potential adverse effects, public health implications, and the need for further scientific evidence before making significant changes to federal drug policies.
The DEA's stance on marijuana rescheduling continues to be a contentious issue, with stakeholders from different sectors, including lawmakers, medical professionals, patients, and industry representatives, voicing their opinions and advocating for their respective positions.
As the Biden administration takes office, the future of marijuana rescheduling remains uncertain. The DEA's authority and approach to scheduling decisions will likely shape the course of federal cannabis policies and influence the ongoing state-federal conflicts surrounding marijuana Legalization.
